UNIVERSITY OF MIAMI Curriculum Vitae Standard Format

1. Date: February, 2014 I. PERSONAL 2. Name: Ram P. Agarwal 3. Home Phone 4. Office Phone: (305) 243-4817 5. Home Address: n/a 6. Current Academic Rank: Associate Professor 6a. Tenured 7. Primary Department: Medicine 8. Secondary or Joint Appointment: NONE 9. Citizenship: United States 10. Visa Type (if non-citizen): NONE II. HIGHER EDUCATION 11. Institutional (institution; degree; date conferred): Banaras Hindu University Biochemistry Ph.D. 1967 Varanasi, India Lucknow University Chemistry/Biochemistry M.Sc. 1959 Lucknow, India 12. Non-Institutional (description; dates): NONE.

1

13. Certification, licensure (description; board or agency; dates): NONE. III. EXPERIENCE 14. Academic (institutions; rank/status; dates): 1959-1962 Instructor of Chemistry, Indian School of Mines, Dhanbad, India. Studied recovery of metals from industrial waste. Taught chemistry to mining engineering undergraduates. 1962-1963 Research Fellow, Departments of Pathology and Chemistry, K.G.

Medical College, Lucknow University, Lucknow, India. 1963-1966 Demonstrator/Lecturer, Biochemistry and Medicinal Chemistry,

Banaras Hindu University, Varanasi, India. Studied effects of radiations on nucleic acid metabolism in bacteria. Taught biochemistry to medical undergraduates. 1967-1971 Research Associate/Instructor, Biomedical Sciences, Brown University,

Providence, RI. 1970-1972 Enzymologist/Clinical Chemist, Rhode Island Hospital, Providence, RI. 1971-1977 Assistant Professor, Biochemical Pharmacology, Brown University,

Providence, RI. 1977 Associate Professor of Biochemical Pharmacology, Brown University,

Providence, RI. Studied drug metabolism; purification and characterization of enzymes; inhibitors of nucleoside and nucleotide metabolism; directed clinical laboratory dealing with the genetic errors in metabolism. Involved in teaching of biochemical pharmacology to undergraduates.

1977-1985 Associate Professor of Pharmacology and Research Medicine, Boston University School of Medicine, Boston, MA.

In-charge of the Biochemical Pharmacology Laboratory, directed research in: experimental and clinical cancer chemotherapy; development of new methods of monitoring drug concentrations, metabolism, resistance and ways of potentiation of their chemotherapeutic effects; pharmacokinetics and exploration of new ways of drug delivery system. Teaching cancer chemotherapy to undergraduates and postgraduates.

1985-1991 Research Associate Professor of Oncology/Manager, Analytical Pharmacology Resource, University of Miami School of Medicine, Miami, FL.

2

As a manager of the Analytical Pharmacology Resource directed research as above.

1991-1997 Associate Professor of Medical Oncology, University of Miami School of Medicine, Miami, FL.

Continuing research in the above field and the mechanisms of action of anti-AIDS agents.

Training postgraduate scientists. 1997-Present Associate Professor of Medicine, University of Miami School of Medicine, Miami, Florida.

Continuing research in the above field and the mechanisms of action of anti-AIDS and anticancer agents. Training postgraduate Scientists.

15. Hospital Appointments: NONE 16. Non-Academic (employers; title; responsibilities; dates): NONE. 17. Military (branch; rank; responsibilities; dates): NONE.

3

IV. PUBLICATIONS [author(s) (in actual precedence of authorship); title; publisher or journal name; date; page numbers] 18. Books and monographs published (13): 1. Agarwal RP, Bell R, Lillquist A, McCaffrey R: Purine metabolism in leukemia. In

"Adenosine Deaminase in Disorders of Purine Metabolism and in Immune Deficiency," (GL Tritsch, editor). Ann NY Acad Sci 451:160-168, 1985.

2. Bell R, Agarwal RP, Lillquist A, McCaffrey R: Biochemical markers in neoplastic

lymphoid cells. In Immunology of the Lymphomas (SB Sutcliffe, editor). CRC Press, Inc., Boca Raton, Florida, p 153-166, 1985.

3. Agarwal RP: Adenosine deaminase: Measurement of activity and use of inhibitors

in "Methods used in adenosine Research" (DM Paton, editor). Plenum Publishing Corporation, New York. Methods in Pharmacology 6:109-125, 1985.

4. Agarwal RP, Parks RE Jr, and Rogler-Brown T: Role of the cell membrane in the

interaction of adenosine deaminase and deoxycoformycin. In The Inborn Errors of Specific Immunity (B Pollara, RJ Pickering, HJ Meuwissen and IH Porter, editors). Academic Press, New York, p 297-313, 1979.

5. Parks RE Jr, Agarwal KC, Agarwal RP, Crabtree GW, Rogler-Brown T, Savarese

TM and Stoeckler JD: Biochemical factors that influence the therapeutic potential of purine analogs in Nucleosides, Nucleotides and Their Biological Application (JL Barascut and JL Imbach, editors). INSERM, Paris, Vol 81, p 209-237, 1978.

6. Agarwal RP, Robinson B, Parks RE Jr: Nucleoside diphosphokinase from human

erythrocytes. In Methods of Enzymology (Edited by PA Hoffee, ME Jones). Academic Press, New York, Vol 51, p 376-386, 1978.

7. Stoeckler JD, Agarwal RP, Agarwal KC, Parks RE, Jr: Purine nucleoside

phosphorylase from human erythrocytes. In Methods of Enzymology (Edited by PA Hoffee, ME Jones) Academic Press, New York Vol 51, P 530-538, 1978.

8. Agarwal RP, Parks RE Jr: Adenosine deaminase from human erythrocytes. In

Methods of Enzymology (Edited by PA Hoffee, ME Jones). Academic Press, New York, Vol 51, p 502-507, 1978.

9. Agarwal RP, Cha S, Crabtree GW, Parks RE Jr: Coformycin and deoxycoformycin:

Tight-binding inhibitors of adenosine deaminase. In the Chemistry and Biology of Nucleosides and Nucleotides. (RE Harmon, RK Robins and LB Townsend, editors). Academic Press, New York, p 159-197, 1978.

4

10. Agarwal RP, Agarwal KC, Parks RE Jr: A general method for isolation of various enzymes. In Methods of Enzymology (Edited by PA Hoffee, ME Jones). Academic Press, New York, Vol 51, p 581-586, 1978.

11. Parks RE Jr, Crabtree GW, Kong CM, Agarwal RP, Agarwal KC, Scholar EM:

Incorporation of analog purine nucleosides into the formed elements of human blood. Ann NY Acad Sci 255: 412-434, 1975.

12. Parks RE Jr, Agarwal RP: Nucleoside diphosphokinase. In The Enzymes. Third

edition. (Edited by PD Boyer). Academic Press, New York, Vol 8, p 307-333, 1973. 13. Parks RE Jr, Agarwal RP: Purine nucleoside phosphorylase. In The Enzymes.

Third edition (Edited by PD Boyer) Academic Press, New York, Vol 7, p 483-514, 1972.

19. Juried or refereed journal articles and exhibitions (63): 1. Subbarayan PR, Sarkar M, Impellizeri S, Raymo F, Lokeshwar BL, Kumar P,

Agarwal RP, and Ardlan B. Anti-proliferative and anti-cancer properties of Achyranthes aspera: specific inhibitory activity against pancreatic cancer cells. J Ethnopharmacol 131: 78-82, 2010.

2. Han T, Fernandez M, Chou T-C, and Agarwal RP. Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells. J Cancer Res Clin Oncol. 131: 609-616,2005.

3. Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE, and Agarwal RP.

Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Bichem Pharmacol. 70: 426-432, 2005.

4. Saiko P, Horvath Z, Illmer C, Medlener S, Baur W, Hoechll T, Erlach N, Grusch

M, Krupitza G, Mader RM, Jaeger W, Schott H, Agarwal RP, Fritzer-Szekeres M and Szekeres T. Cytotoxic effects of novel ampiphilic dimers consisting of 5-fluorodeoxyuridine and arabinosylcytosine in cross-resistant H9 human lymphoid cells. Leukemia Res. 29:785-791, 2005.

5. Patel M, Agarwal R, and Ardalan B. Effect of oxaliplatin and CP11 on cytotoxicity

and nucleic acid incorporation of the fluoropyrimidines. J Cancer Res and Clin Oncol. 130:453-459, 2004.

6. HanT, Fernandez M, Sarkar M, and Agarwal RP. 2’,3’-Dideoxycytidine represses

thymidine kinases 1 and 2 expression in T-lymphoid cells. Life Sciences. 74: 835-842, 2004.

5

7. Han T, Fernandez M, Chou T-C, and Agarwal RP. 2-Chloro-2’-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells. Biochem Biophys Res Commun. 316: 518-522, 2004.

8. Han T, Fernandez M, Sarkar M, and Agarwal RP. Arabinosylcytosine down-

regulates thymidine kinase and induces cross-resistance to zidovudine in T-lymphoid cells. Biochem Biophys Res Commun. 307: 564 –568, 2003.

9. You Z, Mian AM, Agarwal RP, and Lee HJ. Synthesis, anti-HIV, and cytotoxic

activity of new AZT conjugates of steroid acids. Nucleosides, Nucleotides and Nucleic acids. 22: 2049-2060, 2003.

10. Agarwal RP, Han T, Fernandez M. Reduced cellular transport and activtion of

fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol. 61: 39-47, 2001.

11. Agarwal RP, Wang W, Yo P, Han T, and Fernandez M. Cross resistance of

dideoxycytidine resistant cell lines to azidothymidine. Biochem Pharmacol. 58: 1603-1608, 1999.

12. Agarwal RP, Han T, and Fernandez M. Collateral resistance of a

dideoxycytidine-reistant cell line to 5’-fluoro-2’-deoxyuridine. Biochem Biophys Res Commun. 262: 657-660, 1999.

13. Lee RK, Cai J-P, Deview V, Gill PS, Cabral L, wood C, Agarwal RP, Xia W,

Boise LH, Podack E, and Harrington Jr. WJ. Azidothymidine and interferon induced apoptosis in Herpes virus associated lymphomas. Cancer Res. 59: 5514-5520, 1999.

14. Agarwal RP and Olivero OA: Genotoxicity and mitochondrial damage in human

lymphocytic cells chronically exposed to 3'-azido-2',3'-dideoxythymidine (AZT). Mutation Res.390: 223-231, 1997.

15. Agarwal RP, He J, Bansal M and Gupta V: Effect of long-term zidovudine

exposure on salvage and de novo purine and pyrimidine nucleotide synthesis. Biochim. Biophys. Acta.266: 223-228, 1995.

16. Agarwal RP and He J: Effect of hydroxyurea on 2',3'-dideoxycytidine activation.

Biochem Biophys Res Commun 205: 92-97, 1994. 17. Agarwal RP, Padmanabhan J and He J: Kinetics of accumulation and efflux of

3'-azido-3'-deoxythymidine 5'-monophosphate in H9 and H9-AZT cells. Cellu Pharma 1:121-125, 1994.

6

18. Agarwal RP: Increased activation of 2',3'-dideoxycytidine by acivicin. Biochem Biophys Res Commun 202:1524-1529, 1994.

19. Bruce Gregorios JH, Lin L, Ramirez A and Agarwal RP: Effects of cyclic AMP

and butyrate on cell cycle, DNA, RNA and purine synthesis of astrocytes in culture. Neurochem Res 17:315-350,1992.

20. Agarwal RP, Lin L, Padmanabhan J and Duncan RC: Effect of acivicin on 1-β-

D-arabinofuranosylcytosine resistant L1210 cells: Modulation by nucleosides and dipyridamole. J Cell Pharmacol 2:279-283, 1991.

21. Bruce -Gregorios JH, Ramirez A, Lin L, Agarwal RP and Norenberg MD:

Peripheral-type benzodiazepins inhibit proliferation of astrocytes in primary culture. Brain Res 564:167-170, 1991.

22. Bruce-Gregorios JH, Agarwal RP, Oracion A, Ramirez A and Lin L: Effects of

methotrexate on RNA and purine synthesis of astrocytes in primary culture. J Neuropathol 50:770-778, 1991.

23. Agarwal RP and Mian AM: Thymidine and zidovudine metabolism in

chronically zidovudine exposed cells in vitro. Biochem Pharmacol 42:905-911, 1991.

24. Agarwal RP, Lin L, Padmanabhan J and Duncan RC: Effect of nucleosides and

nucleoside transport inhibitors on acivicin induced cytotoxicity on L1210 cells. Intl J Purine and Pyrimidine Res 2:97-102, 1991.

25. Agarwal RP: 3'-Azido-2'-3'-Dideoxythymidine induces thymidine kinase activity

in vitro. Intl J Purines and Pyridimine Res 2:1-3, 1991. 26. Fischl MA, Uttamchandani RB, Resnick L, Agarwal R, Fletcher MA, Patrone-

Reese J, Dearmas l, Chidekel J, McCann M and Myers M: A phase I study of recombinant human interferon alfa-2A or human lymphoblastoid interferon alfa-1 and concomitant zidovudine in patients with AIDS related Kaposi's sarcoma. J AIDS 4:1-10, 1991.

27. Sridhar KS, Samy TS, Agarwal RP, Duncan RC, Benedetto P, Krishan A, Vogel

CL, Feun LG, Savaraj NM, Richman SP and Zubrod CG: Phase I study of pirarubicin (4'-0-tetrahydropyranyladriamycin): Clinical pharmacology and pharmacokinetics. Cancer 66:2082-2091, 1990.

28. Agarwal RP, Busso ME, Mian AM and Resnick L: Uptake of

2',3'-dideoxyadenosine in human immunodeficiency virus infected and noninfected human cells. AIDS Res Human Retrovirus 5:527-529, 1989.

7

29. Vogel CL, Gorowski E, Davila E, Eisenberger M, Kosinski J, Agarwal RP and Savaraj N: Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Invest New Drugs 5:187-198, 1986.

30. Lopez JA, Nassif E, Vennicola P, Krikorian JG and Agarwal RP: Central

nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neuro Oncol 3:119-124, 1985.

31. Agarwal RP: Pharmacology of deoxycoformycin and arabinosyladenine. Cancer

Treatment Rep (Symposia) 2:17-22, 1984. 32. Lopez JA, Beardsley GP, Krikorian JG, Mortara RW and Agarwal RP:

Cerebrospinal fluid and plasma pharmacokinetics of high-dose 1-β -D-arabinofuranosylcytosine in non-human primates. Cancer Res 43:5190-5193, 1983.

33. Major PP, Agarwal RP and Kufe DW: Clinical pharmacology of

arabinofuranosyladenine in combination with deoxycoformycin. Cancer Chemother Pharmacol 10:125-128, 1983.

34. Agarwal RP, Blatt J, Miser J, Sallan S, Lipton JM, Reaman GR, Holcenberg J

and Poplack DG: Clinical pharmacology of adenine arabinoside in combination with 2'-deoxycoformycin. Cancer Res 42:3884-3886, 1982.

35. Agarwal RP, Major PP and Kufe DW: Simple and rapid high performance liquid

chromatographic method of analysis of nucleosides in biological fluids. J Chromatogr (Biomed. Application) 231:418-424, 1982.

36. Agarwal RP: Inhibitors of adenosine deaminase (A Review Article). J

Pharmacol and Ther 17:399-429, 1982. 37. Agarwal RP: Purine nucleoside kinases in mouse tissue and human lymphoid

cells in culture. Comp Biochem Physiol 70B:595-599, 1981. 38. Major PP, Agarwal RP and Kufe DW: Clinical pharmacology of

deoxycoformycin. Blood 58:91-96, 1981. 39. Major PP, Agarwal RP, Kufe DW: Deoxycoformycin: Neurological toxicity.

Cancer Chemother Pharmacol 5:193-196, 1981. 40. Agarwal RP: In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin

in mouse blood and leukemia L1210 cells. Biochem Pharmacol 29:187-193, 1980.

8

41. Agarwal RP: Deoxycoformycin toxicity in mice after long term treatment. Cancer Chemother Pharmacol 5:83-87, 1980.

42. Walsh CT, Craig RW, Agarwal RP: Increased activation of 1-B

-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells. Cancer Res 40:3286-3292, 1980.

43. Agarwal RP: Recovery of 2'-deoxycoformycin inhibited adenosine deaminase of

mouse erythrocytes and leukemia L1210 in vivo. Cancer Res 39:1425-1427, 1979.

44. Crabtree GW, Agarwal RP, Parks RE Jr, Lewis AF, Wotring LL and Townsend

LB: N-Methylformycins: Reactivity with adenosine deaminase, incorporation into intracellular nucleotides of human erythrocytes and L1210 cells and cytotoxicity to L1210 cells. Biochem Pharmacol 28:1491-1500, 1979.

45. Rogler-Brown T, Agarwal RP, Parks RE Jr: Tight-binding inhibitors: VI. The

interactions of deoxycoformycin and adenosine deaminase in intact human erythrocytes and Sarcoma 180 cells. Biochem Pharmacol 27:2289-2296, 1978.

46. Stoeckler JD, Agarwal RP, Agarwal KC, Schmid K, Parks RE Jr: Purine

nucleoside phosphorylase from human erythrocytes: Physicochemical properties of the crystalline enzyme. Biochemistry 17:278-283, 1978.

47. Agarwal RP, Parks RE Jr: Potent inhibition of muscle 5'-AMP deaminase by the

nucleoside antibiotics coformycin and deoxycoformycin. Biochem Pharmacol 26:663-666, 1977.

48. Agarwal RP, Spector T, Parks RE Jr: Tight-binding inhibitors: IV. Inhibition of

adenosine deaminase by various inhibitors. Biochem Pharmacol 26:359-367, 1977.

49. Agarwal RP, Crabtree GW, Parks RE Jr, Nelson JA, Keightley R, Parkman R,

Rosen FS, Stern RC, Polmar SH: Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J Clin Invest 57:1025-1035, 1976.

50. Cha S, Agarwal RP, Parks RE Jr: Tight-binding inhibitors: II. Non-steady-state

nature of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin. Biochem Pharmacol 24:2187-2197, 1975.

51. Agarwal RP, Parks RE Jr: A possible association between the nucleoside

transport system of human erythrocytes and adenosine deaminase. Biochem Pharmacol 24:547-550, 1975.

9

52. Agarwal KC, Agarwal RP, Stoeckler JD, Parks RE Jr: Purine nucleoside

phosphorylase: Microheterogeneity and comparison of kinetic behavior of the enzyme from several tissues and species. Biochemistry 14:79-84, 1975.

53. Agarwal RP, Sagar SM, Parks RE Jr: Adenosine deaminase from human

erythrocytes: Purification and effects of adenosine analogs. Biochem Pharmacol 24:693-701, 1975.

54. Parks RE Jr, Brown PR, Cheng Y-C, Agarwal KC, Kong CM, Agarwal RP,

Parks CC: Purine metabolism in primitive erythrocytes. Comp Biochem Physiol 45B:335-364, 1973.

55. Senft AW, Crabtree GW, Agarwal KC, Scholar EM, Agarwal RP, Parks RE Jr:

Pathways of nucleotide metabolism in Schistosoma mansoni: III. Identification of enzymes in cell-free extracts. Biochem Pharmacol 22:449-458, 1973.

56. Brown RP, Agarwal RP, Gell J, Parks RE Jr: Nucleotide metabolism in the

whole blood of various vertebrates: Enzyme levels and the use of high pressure liquid chromatography for the determination of nucleotide patterns. Comp Biochem Physiol 43B:891-904, 1972.

57. Agarwal RP, Parks RE Jr: Erythrocytic nucleoside diphosphokinase: V. Some

properties and behavior of the pI 7.3 isozyme. J Biol Chem 246:2258-2264, 1971. 58. Cheng Y-C, Agarwal RP, Parks RE Jr: Erythrocytic nucleoside diphosphokinase.

IV. Evidence for electrophoretic heterogeneity. Biochemistry 10:2139-2143, 1971.

59. Agarwal RP, Parks RE Jr: Purine nucleoside phosphorylase from human

erythrocytes: V. Content and behavior of sulfhydryl groups. J Biol Chem 246:3763-3768, 1971.

60. Agarwal RP, Scholar EM, Agarwal KC, Parks RE Jr: Identification and isolation

on a large scale of guanylate kinase from human erythrocytes: Effects of monophosphate nucleotides of purine analogs. Biochem Pharmacol 20:1341-1354, 1971.

61. Agarwal RP, Parks RE Jr: Purine nucleoside phosphorylase from human

erythrocytes: IV. Crystallization and some properties. J Biol Chem 244:644-647, 1969.

62. Agarwal RP, Mehrotra RML: Changes in the "soluble" and "insoluble" glycogen

fractions of the liver and skeletal muscle of the rats fed para-aminosalicylate. Ind J Med Res 55:428-434, 1967.

10

63. Agarwal RP, Guha A: Lytic action of chlorpromazine-hydrochloride on E. coli G

cells. Br J Pharmacol Chemother 24:466-469, 1965. 20. Other works and publications (60): 1. Sarkar M, Damaraju VL, Carpenter P, Cass CE and Agarwal RP. Reduced

nucleoside transporter protein in arabinosylcytosine (araC) resistant human lymphoid cells. Proc Am Assoc Cancer Res 46: A5074, 2005.

2. Sarkar M, Han T, and Agarwal RP. Reduced transcription factor Sp1 in

arabinosylcytosine resistant H9 cells. Proc Am Assoc Cancer Res. 45: A600, 2004. 3. Sarkar M, Han T, Agarwal RP. Epigenetic factors responsible for reduced

deoxycytidine kinase activity in Arabinosylcytosine and dideoxycytidine resistant H9 lymphoid cells. Proc Am Assoc Cancer Res. 44: 115, 2003.

4. Greer S, Wozniak C, Arnold D, Thurer R, Agarwal R, and Mian A. Pyrimidine

metabolizing enzyme-driven cancer therapy, radiation therapy and selective rescue. Miami Nature Biotechnology Winter Symposium. 14: 55, 2003.

5. Wu CJ, Wangpaichitr M, Yang LY, Agarwal R, Feun L, Lampidis T, Robles C, and

Savaraj N. Collateral Sensitivity to nucleoside/purine analogs in cisplatin resistant cell lines. Proc Am Assoc Cancer Res. 43: 955, 2002.

6. Agarwal RP and Han T. Lamivudine induced activation of azidothymidine. Proc Am

Assoc Cancer Res. 42: 81, 2001. 7. Fernandez M, Han T, and Agarwal RP: 2-Chlorodeoxyadenosine enhances

phosphorylation of AZT in dideoxycytidine (ddC) resistant cells. Proc Am Assoc Cancer Res 41: 865, 2000.

8. Fernandez M, Han T, Yo P, Wang W, and Agarwal RP: Comparison of

arabinosylcytosine and dideoxycytidine induced drug resistance in H9 cells. Proc Am Assoc Cancer Res 40: 676, 1999.

9. Agarwal RP, Wang W, and Yo P: Characteristics of 2’,3’-dideoxycytidine (ddC) nd

arabinosylcytosine (araC resistance in human lymphocytic cell lines. Proc. Am Assoc Cancer Res 39: 216, 1998.

10. Agarwal RP: 2’,3’-dideoxycytidine (ddC) induced drug resistance in human lymphocytic cell line. Proc Am Assoc Cancer Res 38: 482, 1997.

11

11. Agarwal RP: Zidovudine (AZT) increases thymidine kinase activity in cultured cells. Proc Am Assoc Cancer Res 37: 362, 1996.

12. Agarwal RP, He J, Bansal M, and Gupta V: Hydroxyurea (HU) increases activation

of 2',3'-dideoxycytidine (ddC). Proc Am Assoc Cancer Res 36: 404, 1995. 13. Agarwal RP, Bansal M, and Gupta V: Effect of chronic azidothymidine (AZT)

exposure on purine and pyrimidine nucleotide synthesis in H9 cells. The FASEB J 9: A94, 1995.

14. Agarwal RP and Olivero OA: Chromosomal aberrations in H9 cells chronically

exposed to 3'azido-2,'3'-dideoxythymidine (AZT) in vitro. Proc Am Assoc Cancer Res 35:311, 1994.

15. Agarwal RP, and He J: Effect of prolonged zidovudine (AZT) exposure on purine salvage and de novo nucleotide synthesis. Proc. Am Assoc Cancer Res 34:281, 1993.

16. Agarwal RP, Padmanabhan J and He J: Efflux of azidothymidine monophosphate in

H9 and H9-AZT cells. Proc Am Assoc Cancer Res 33:553, 1992.

17 Agarwal RP: Effect of zidovudine (AZT) on 2'-deoxythymidine salvage in H9 cells. Proc Am Assoc Cancer Res 32:415, 1991.

18. Agarwal RP: Increased thymidine kinase activity in cells grown in 3'-azido,2'-

deoxythymidine (AZT) containing medium. Proc Am Assoc Cancer Res 31:395, 1990.

19. Agarwal RP, Kolonias D, Krishan A, Uttamchandani R and Fischl MA:

Pharmacokinetics of azidothymidine in patients with AIDS related Kaposi's sarcoma. The Pharmacologist 30:A156, 1988.

20. Busso ME, Nwosu C, Agarwal RP and Resnick L: Studies on the metabolism and

uptake of dideoxyadenosine (ddAdo) in human lymphocytes. Fourth Intl Conf AIDS, Stockholm, June 12-16, 1988.

21. Resnick L, Busso M, Mian AM and Agarwal RP: Anti-HIV activity of nucleoside

dimers in vitro. Fourth Intl Conf AIDS, Stockholm, June 12-16, 1988. 22. Fischl M, Reese J, Dearmas L, Resnick L, Fletcher M, Agarwal R and Myers M:

Phase I study of interferon-alpha and AZT in patients with AIDS-related Kaposi's sarcoma. Fourth Intl Conf AIDS, Stockholm, June 12-16, 1988.

23. Sridhar KS, Samy TSA, Agarwal RP, Duncan RC, Benedetto P, Feun LG, Krishan A

and Zubrod CG: Phase I study of 4'0-tetrahydropyranyladriamycin (THP-ADR). Proc Am Assoc Cancer Res 27:185, 1988.

12

24. Agarwal RP, Busso ME, Mian AM and Resnick L: Studies on the intracellular accumulation of 2',3'-dideoxyadenosine. Proc Am Assoc Cancer Res 27:347, 1988.

25. Agarwal RP: In vitro collateral sensitivity (CS) of arabinosylcytosine (Ara-C)

resistant murine leukemias with acivicin. Proc Am Assoc Cancer Res 28:280, 1987.

26. Agarwal RP and Ragland D: Enhancement of chemotherapeutic activity of arabinosylcytosine by hydroxyurea in intracranial L1210 leukemia bearing mice. Proc Am Assoc Cancer Res 27:379, 1986.

27. Vogel C, Davila E, Agarwal R, Gorowski E and Savaraj N: Phase I trial and

pharmacokinetics of weekly ICRF-187: A Southeastern Cancer Study Group Pilot. Proc Am Soc Clin Oncol 5:35, 1986.

28. Agarwal RP: Chemotherapeutic potential of adenosine deaminase inhibitors.

Indian J Pharmacol 17 (Suppl 1):0-206, 1985. 28. Lopez J, Pliner L, Bell R, McCaffrey R and Agarwal RP: Study of high-dose

cytosine arabinoside and cisplatin chemotherapy for non-hematologic malignancies. Proc Am Soc Clin Oncol 3:31, 1984.

29. Hoppe H, Lopez J, Hollander D, Agarwal R and Devereux D: Efficacy of

1-β-D-arabinofuranosyl cytosine (Ara-C) against murine fibrosarcoma. Proc Am Assoc Cancer Res 25:350, 1984.

30. Agarwal RP, Codner M and Hoppe H: Cell cycle alterations induced in HL60 cells

by 9-β-D- arabinofuranosyl-2-fluoroadenine (F-Ara-A). Proc Am Assoc Cancer Res 25:350, 1984. 31. Dimond P and Agarwal RP: In vitro metabolism of

9-β-D-arabinofuranosyl-2-fluoroadenine-5'- phosphate (F-Ara-AMP) by human blood. Fed Proc (Fed Am Soc Exp Biol) 42:211, 1983.

32. Lopez JA, Krikorian JG, Beardsley GP and Agarwal RP: Cerebrofluid

pharmacokinetics of cytosine arabinoside (Ara-C). Proc Am Assoc Cancer Res 23:210, 1982.

33. Major PP, Agarwal RP and Kufe DW: Clinical pharmacology of the Ara-A/DCF

combination. Proc Am Soc Clin Oncol 1:29, 1982. 34. Lopez JA, Krikorian JG, Lopez AJ and Agarwal RP: Sustained cytotoxic CSF Ara-C

levels following high dose i.v. bolus infusion. Proc Am Assoc Cancer Res 22:361, 1981.

13

35. Miller BR, Agarwal RP: Differences in nucleoside kinases in neonatal and adult mouse liver. Proc Am Assoc Cancer Res 22:17, 1981.

36. Agarwal RP: Recovery of deoxycoformycin (DCF) inhibited adenosine deaminase

(ADA) of mouse tissues. The Pharmacologist 22:239, 1980. 37. Osband M, Gallison D, Miller B, Agarwal R and McCaffrey R (sponsored by N.P.

Rosiman): Concanavalin A activation of suppressor cells is mediated by the release of histamine and is blocked by cimetidine. Clin Res 28:356A, 1980.

38. Kufe D, Major P, Agarwal RP, Sallan S and Frei E III: Phase I-II trial of

deoxycoformycin (DCF) in T-cell malignancies. Proc Am Assoc Cancer Res 21:328, 1980.

39. Agarwal RP, Walsh CT and Craig RW: Effect of hydroxyurea on metabolism of

1-β-D- arabinofuranosylcytosine in L1210 cells in mice and in vitro. Proc Am Assoc Cancer Res 21:13, 1980.

40. Craig RW, Walsh CT, Agarwal RP: Effect of hydroxyurea on distribution of 1-β-D-

arabinofuranosylcytosine in mice bearing L1210 ascites cells. Ninth Annual Meeting New England Pharmacologists. University of Connecticut, Storrs, Connecticut, January 25-26, 1980.

41. Walsh CT, Craig RW, Agarwal RP: Increased activation of

1-β-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells. Fed Proc (Fed Am Soc Exp Biol) 38:370, 1979.

42. Craig RW, Walsh CT, Agarwal RP: Increased activation of cytosine arabinoside

(Ara-C) by hydroxyurea in L1210 cells. Eighth Annual Meeting, New England Pharmacologists, Norwich, Connecticut, February, 1979.

43. Agarwal RP: Interactions of 2'-deoxycoformycin and adenosine deaminase in

leukemia L1210 in vivo and in vitro. Proc Am Assoc Cancer Res 20:12, 1979. 44. Agarwal RP: In vivo and in vitro inhibition of mouse blood adenosine deaminase by

deoxycoformycin. Fed Proc (Fed Am Soc Exp Biol) 37:1541, 1978.

45. Agarwal RP, Brown TL, Parks RE Jr: Inhibition of adenosine deaminase in intact human erythrocytes. The Pharmacologist 19:150, 1977.

46. Crabtree GW, Agarwal RP, Parks RE Jr, Lewis AF, Townsend LB: Incorporation of

N-methylformycins into nucleotide pools of human erythrocytes. Proc Am Assoc Cancer Res 18:181, 1977.

14

47. Hamill S, Agarwal RP, Parks RE Jr: Entrapment of enzymes in erythrocytic ghosts. Sixth Annual Meeting, New England Pharmacologist, Newport, RI, January 21-23, 1977.

48. Agarwal RP, Cha S, Crabtree GW, Parks RE Jr: Coformycin and deoxycoformycin:

Tight-binding inhibitors of adenosine deaminase. Symposium on Nucleoside and Nucleotide Chemistry. Am Chem Soc Meeting, San Francisco, August, 1976.

49. Parks RE Jr, Agarwal RP, Crabtree GW, Agarwal KC: Role of adenosine

deaminase (ADA) in the incorporation of adenosine analogs into the nucleotide pools of human erythrocytes and other blood elements. The Pharmacologist 18:156, 1976.

50. Agarwal RP, Cha S, Parks RE Jr: Inhibitors of adenosine deaminase: Reversible,

semi-tight-binding and tight-binding. The Pharmacologist 18:117, 1976.

51. Agarwal RP, Crabtree GW, Agarwal KC, Parks RE Jr, Townsend LB: Human erythrocytes: A possible tool for identification of adenosine analogs of chemotherapeutic potential. Proc Am Assoc Cancer Res 17:214, 1976.

52. Agarwal RP, Parks RE Jr: Comparison of the nature of inhibition of human

erythrocytic adenosine deaminase by various inhibitors. Fifth Annual Meeting, New England Pharmacologists, Farmington, Connecticut, January 30-31, 1976.

53. Parks RE Jr, Crabtree GW, Kong CM, Agarwal RP, Agarwal KC, Scholar EM:

Incorporation of analog purine nucleosides into the formed elements of human blood. The Conference on the Chemistry, Biology and Clinical Uses of Nucleoside Analogs, The NY Academy of Sciences, September 4-6, 1976.

54. Agarwal RP, Burgess N, Driesman M, Parks RE Jr: Inhibition of human erythrocytic

adenosine deaminase by coformycin: Studies with the isolated enzyme and the intact cells. The Pharmacologist 16:266, 1974.

55. Agarwal KC, Agarwal RP, Parks RE Jr: Electrophoretic heterogeneity and

physiochemical properties of human erythrocytic purine nucleoside phosphorylase. Fed Proc 32:581, 1973.

56. Agarwal RP, Sagar SM, Parks RE Jr: Effects of adenosine analogs on human

erythrocytic adenosine deaminase. Fed Proc (Fed Am Soc Exp Biol) 32:512, 1973. 57. Agarwal RP, Sagar SM, Parks RE Jr: Specificity of human erythrocytic adenosine

deaminase. Second Annual Meeting, New England Pharmacologists, Hanover, NH, February 15-16, 1973.

15

58. Agarwal KC, Agarwal RP, Parks RE Jr: Electrophoretic heterogeneity of purine nucleoside phosphorylase in different species. Second Annual Meeting, New England Pharmacologists, Dartmouth Medical School, Hanover, NH, February 15-16, 1973.

59. Crabtree GW, Agarwal KC, Agarwal RP, Brown PR, Scholar EM, Stegman RE,

Senft D, Senft AW, Parks RE Jr: Some aspects of purine metabolism in Schistosoma mansoni. First Annual Meeting, New England Pharmacologists, Yale University School of Medicine, New Haven, Connecticut, January 27-28, 1972.

60. Crabtree GW, Agarwal KC, Agarwal RP, Brown PR, Scholar EM, Senft D, Senft

AW, Parks RE Jr: Pathways of purine metabolism in Schistosoma mansoni. The Pharmacologist 13:311, 1971.

61. Parks RE Jr, Agarwal KC, Agarwal RP, Brown PR, Chen Y-C, Kong CM, Parks CC:

Purine metabolism in primitive erythrocytes. The Bulletin, Mount Desert Island Biol. Laboratory, Salisbury Cove, Maine 11:75, 1971.

62. Parks RE Jr, Cheng Y-C, Agarwal RP: Nucleoside diphosphokinase: Occurrence of

six isozymes in human erythrocytes. Fed Proc (Fed Am Soc Exp Biol) 30:1171, 1971.

63. Agarwal RP, Parks RE Jr: Purine nucleoside phosphorylase from human

erythrocytes: Presence of multiple sulfhydryl groups of different reactivity. Proc Am Assoc Cancer Res 12:87, 1971.

64. Agarwal RP, Parks RE Jr: Human erythrocytic purine nucleoside phosphorylase:

Evidence for multiple sulfhydryl groups. Second Northeast Regional Meeting, Am Chem Soc, p 62, October, 1970.

65. Cheng Y-C, Agarwal RP, Parks RE Jr: Erythrocytic nucleoside diphosphokinase:

Occurrence of several isozymes in human erythrocytes. Second Northeast Regional Meeting, Am Chem Soc, p 71, October, 1970.

66. Agarwal RP, Parks RE Jr: Human erythrocytic purine nucleoside phosphorylase:

Crystallization and characterization. Fed Proc (Fed Am Soc Exp Biol) 27:585, 1968. 21. Other works accepted for publication: Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE, Agarwal RP. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochemical Pharmacol (Accepted for publication pending minor revisions) V. PROFESSIONAL 22. Funded Research Performed (

16

ACS-IN-51Z New Approaches to Combat Drug Resistance. $ 6,000 Aug 1985 – Jul 1986 (RP Agarwal, PI)

NIH-BRSG-RR05363 Novel Approaches to Combat Drug Resistance

$10,000 Apr 1986 – Mar 1988 (RP Agarwal PI).

NIH-BRSG-RR05363 Resistance of Human Macrophages to

Dideoxyribonucleosides $10,000 (RP Agarwal PI)

NIH-AI U01 27675 AIDS Treatment Evaluation Unit Grant (Dr. Margaret Fischl, PI),

Jun 1986 –Jun 1991 (RP Agarwal, Investigator) NIH-AI-U01 27560 Peditric AIDS Treatment Evaluation Unit (Dr G Scott, PI) Sep

1988 –Sep 1993 (RP Agarwal, Investigator) NIH-AI-U01 25696 Miami-National New Drug Discovery Grant (Dr. A. Krishan, PI),

Oct- 1987 – Sep 1992. (RP Agarwal, Investigator)

NIH-NIAID RO1-AI 29155 Mechanisms of Selective Actions of Antiviral

Agents. Sep 1989 – Apr 2001 (RP Agarwal, PI)

NIH-NIA1D R03-AI 30211 Host Factors Affecting Response to Therapy. $

44,877 direct cost Sep 1990 Set 1991) (RP Agarwal, PI)

SCCC-Univ Miami Retroviral Related Malignancies Program. $5000; from May 1998 – May, 1999 (, UM grant).

Ram P. Agarwal, P.I. NIH RO1-AI29155 Mechanisms of Selective Actions of Antiviral Agents. $ 525,000 direct; $251,503 indirect from May2001-

Apr 2004; Dr. Ram P. Agarwal, P.I. 62% effort. I have continuously had this grant for 12 years.

NIH ARC/RCMI F. Humphries (FAMU) P.I. $147,139 direct; $75,040 indirect from 10/01/99 –

9/30/2003; Ram P. Agarwal (Investigator), 5% effort.

NIH-P30AI073961 G. Scott (PI)

17

$25000 Developmental Project; Evaluation of a Yoga/Meditation Program on the Quality of Life in HIV-infected Crack Cocain Users: A Pilot Feasibility and Acceptability Study (Ram P Agarwal, PI) 06/01/2012 – 05/31/2014.

23. Editorial responsibilities: Served as a member of the Editorial Board of: (i) Carbohydrates, Nucleosides and

Nucleotides; and (ii) International Journal of Purines and Pyrimidine Research. Reviewed grants for NIH, American Cancer Society and VA. Reviewer for many scientific journals. 24. Professional and Honorary Organizations (member; officer; date): American Association for Cancer Research (1978-Present). American Society for Pharmacology and Experimental Therapeutics (1978-Present). Examining Board Memberships: Served as an external examiner of a Ph.D. Thesis of

Banaras Hindu University, Varanasi, India (1985). Member, Board of Directors, Hindu University of America, Orlando, FL (1995-

present). Vice-Chairmen, Board of Directors, Hindu University of America, Orlando, FL (2002-

present). Vice President, American Association of Indian Scientists in Cancer Research, Inc

(AAISCR) (1996- 2003). President, American Association of Indian Scientists in Cancer Research, Inc

(AAISCR) (2003-2005) 25. Honors and Awards: Raptakos Medical Research Fellow (1962-1963).

18

Chaired Scientific Sessions at the Annual Meetings of the New England Pharmacologists (1977, 1979).

American Society of Pharmacology and Experimental Therapeutics (1980). Association of Clinical Biochemists of India (1982). Ad Hoc Study Section Member, National Institute of Allergy and Infectious Diseases,

NIH (1994 - 1995). Regular member of Study Section, National Institute of Allergy and Infectious Diseases, NIH (1995 - 1998). Ad Hoc Study Section Member, National Institute of Health, Oncological Sciences IRG (1999 – 2000). Ad Hoc Study Section Member, National Institute of Health, Center for Scientific Review (2000 –present).

26. Post-Doctoral Fellowships: Brown University 1967-1969 Biochemical Pharmacology Providence, Rhode Island 27. Other Professional Activities (e.g., papers presented; performances; conference

proceedings; seminar or conference panel member; etc.): Scientific presentations at national and international meetings

Annual Meetings of American Society of Experimental Biology (1968; 1973; 1978; 1995).

American Chemical Society (1970; 1976).

American Association for Cancer Research (1971; 1976; 1979; 1980; 1984; 1986; 1987; 1988; 1990; 1991; 1992; 1993; 1994, 1995,1996,1997, 1998, 1999, 2000, 2001,2002,2003,2004, 2005).

Annual Meetings of New England Pharmacologists (1973; 1976; 1977). American Society of Pharmacology and Experimental Therapeutics (1974; 1976;

1977; 1980; 1988, 1995). N.Y. Academy of Sciences (1984). International Symposium on Inborn Errors of Specific Immunity (1978).

19

Annual Conferences of Association of Clinical Biochemists of India (New Delhi) (1982).

Fifth International Work Shop on HIV Drug Resistance, Whistler, Canada (July 3-6, 1996)

Invited outside lectureships: 1975 Department of Biochemistry, Institute of Medical Sciences, Banaras

Hindu University, India. 1975 Department of Physiology, Institute of Medical Sciences, Banaras

Hindu University, India. 1975 Department of Pathology, K. G. Medical College, Lucknow

University, India. 1976 Society of Biological Chemists (India), Central Drug Research

Institute, Lucknow. 1976 American Chemical Society. 1978 Milton Hospital, Milton, MA. 1980 Wisconsin Clinical Center, Madison, WI. 1980 Central Drug Research Institute, India. 1980 Arthur D. Little, Inc., Cambridge, MA. 1980 N. E. University, Boston, MA. 1982; 1983 Pharmacology Department, Boston University Medical Center,

Boston, MA. 1982 Tata Memorial Hospital, Bombay, India. 1982 Institute of Medical Sciences, Banaras Hindu University, India. 1982 Hematology Department, University Hospital, Boston, MA. 1983 Boston Veterans Administration Hospital, Boston, MA. 1984 Veteran Administration Hospital, Albany Medical School, Albany,

NY.

20

1984 NewYork Academy of Sciences, New York, NY. 1985 Pfizer Inc., Central Research, Groton, CT. 1997 Paper Presented at the Plenary Session, International Symposium of

Biochemistry of Macromolecules and Biotechnology, UFPE, Recife, Brazil. Title: The use of purine and pyrimidine analogs as anti-HIV and anti-parasitic agents.

2001 Invited lecture on Drug resistance at the Indian Drugs and

Pharmaceutical Limited. Rishikesh, India. 2002 Invited Lecture on the History of Indian medicine (Ayurveda),

International Conference on India’s Contribution & Influence in the World, Univ. Massachusetts, Darthmouth, MA.

2002 Invited Lecture to a panel of Oncologists on Anti Cancer Drugs.

Rishikesh India. 2004 Zalcitabine (ddC) Induces Cellular Resistance Affecting its antiviral Activity, World Conference on Magic Bullets, Nurenburg, Germany, Sept 9-11, 2004. 2005 Cytarabine Induces Chemo-Resistance to Unrelated Nucleoside Analogs. International Symposium on Translational Research: Apoptosis and Cancer, Trivandrum, India, December 18-21, 2005 2006 History of Ayurveda, Symposium on Yoga and Ayurveda, Hindu University of America, Orlando. 2007 Yoga as a Therapeutic Tool: A brief Overview, Hindu University of America, Orlando 2007 Invited lecture on the Emergence of Cellular Drug Resistance – A Challenging Problem in Chemotherapy –A Symposium on the

Current Trends in Drug Development Research, Central Drug Research Institute, Lucknow, India, February, 2007.

2007 Invited lecture, “AraC Resitance in Cancer Chemotherapy”, Post

Graduate Institute of medical Sciences, Lucknow, India .

21

2009 Invited lecture: “Relevance of Hindu Model in Bioethics”. Symposium on the Indo-US Workshop on Bioethics, Sri Ram Chandra University, Chennai, India, Nov 24th, 2009.

2010 Invited lecture on “Yoga as a Therapeutic Tool: An Overview of Current

Status”. Total Health Conference, Hindu University of America, Orlando, September 24-26th, 2010)

2012 invited lecture on “Yoga Therapy in Cancer”. (Presented at ICCPDT,

Jaipur, Jan 21-22, 2012) 2012 Invited lecture on “Hindu Bioethics in the Present Medical Context”.

(Presented at the 2012 Claremont International Jain Conference on Bioethics: Religious and Spiritual Approaches, August 24-25, 2012, Claremont Lincoln University, Claremont, CA)

2013 “Religio-cultural Sensitivity and the Ethical Conduct of Research”.

Workshop Promoting Bioethical Education in Biomedical Research and Practice January 25-Feb 13th, 2013)

2013 Invited lecture: “Evaluation of A Yoga/Meditation Program On The

Quality Of Life Of HIV-Infected Crack Cocaine Users: A Pilot Feasibility and Acceptability Study”. Presented at Amrit Yoga Institute, Medical Understanding of Yoga, Nov 30th, 2013.

VI. TEACHING 28. Teaching Awards Received: None 29. Teaching: 1959-1962 Chemistry, undergraduate students, Indian School of Mines,

Dhanbad. 1963-1966 Biochemistry, undergraduate and graduate medical students, College

of Medical Sciences, Banaras Hindu University. 1969 Lecture in Bio-Med 240 course, Brown University. 1970 Bio-Med 171, helped in designing and supervising the Biochemical

Pharmacology Lab, Brown University.

22

1971 Lecture on Amino Acid and Protein to graduate nurses, Rhode Island

Hospital, Providence, RI. 1971 Bio 1 (undergraduate Biology), Lectures and Lab, Brown University,

Providence, RI. 1973 Bio 128, Helped in designing and supervising Biochemical

Pharmacology Lab, Brown University. 1974 Bio 123 (undergraduate Biochemistry), Brown University. 1974 Bio 123 (undergraduate Biochemistry), Brown University. 1975 Bio 221 (graduate course in Basic Principles in Chemotherapy),

Brown University. 1978 "Basic Principles in Chemotherapy" (Boston University).

1984-1985 Lectures on Hepatic Toxicity (Boston University). 1997 “Purine and Pyrimidine Metabolism”, a course offered to under

graduates of Biochemistry at the Universidade Federal De Pernamburo, Recife, Brazil.

30. Thesis and Dissertation Advising (chairman or committee member; topic; student

name; date): 1974 Supervised a Summer Research Fellow from Tougaloo College of

Mississippi (Brown University). 1974 Supervised a Summer Research Fellow from Dartmouth Medical

School (Brown University). 1975 Bio 195, An independent study entitled "Purine nucleotide cycle in

rat muscle." (Brown University). 1975 Bio 195, An independent study entitled "Isolation of nucleoside

transporter - adenosine deaminase complex of human erythrocytic membrane." (Brown University).

1976 Bio 196, An independent study entitled "Purine nucleotide cycle in

cancer cells." (Brown University).

23

1976 Bio 195, An independent study entitled "Infusion of enzymes in red blood ells." (Brown University).

1977 Masters thesis on "Kinetics of inhibition of adenosine deaminase by

deoxycoformycin in intact human erythrocytes." (Brown University).

1982 Co-adviser for Ph.D. thesis on "Tissue distribution and metabolism

of adriamycin (ADR) and its analog-N-trifluoroacetyl adriamycin-14-valerate (AD-32) in mice." (Boston University).

1985 Masters thesis on "Pharmacologic basis of activity of platinum

complexes in neoplastic diseases." (Boston University). VII. SERVICE 31. University Committee and Administrative Responsibilities: 1977-1985 Head of Biochemical Pharmacology Laboratory, Boston University

School of Medicine, Boston, MA. 1978-1985 Member of the Committee on Graduate Education in Pharmacology,

Boston University School of Medicine, Boston, MA. 1984-1985 Member, Cancer Education Committee, Boston University School of

Medicine, Boston, MA. 1985-1989 Manager, Analytical Pharmacology Resource, Cancer Center,

University of Miami Medical School, Miami, FL. 1992-2004 Trained four postdoctoral fellows; two minority students, two

undergraduates, and two high school graduates. 1994-2001 Faculty Advisor to Hindu Student Council, University of Miami,

Miami, FL. 1997-present Member of the Admission Committee of Medical School, University

of Miami, Miami, FL. 2008-present Member of the Protocol Review Committee, Sylvester Cancer

Center. 2008-present CITI Program. CITI Program India- Coordinator 32. Community Activities: 1967-1968 President, Indian Students Association of Greater Providence.

24

1975-Present Member, Governing Council of Vishwa Hindu Parishad of America (An International Hindu Organization).

1981-1984 President, Vishwa Hindu Parishad of America.

1979-1983 Director, Hindu Youth Camp.

1983-1984 Member, Board of Directors of American Cancer Society, Milton/Quincy Chapter.

1985-1995 Chairman, Advisory Committee of Vishwa Hindu Parishad of

America. 1995-present Member , Advisory Committee of Vishwa Hindu Parishad of

America. 1998, 1999 Lectures on “Basic Principles of Hinduism” in the Department of

Religious Studies at FIU, Miami, FL. 1999 Lecture on “Some Misunderstood Aspects of Hinduism” at the

Theosophical Society of Miami.

2000-2001 Teaching conversational Hindi to UM students. 2003 Chairman, Community Advisor Board on Indian Studies, Florida

International University, Miami. 2004-present Member of the Board of Advisors, Center for Spirituality, Florida

International University, Miami.

25